160 related articles for article (PubMed ID: 29618692)
41. Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials.
Stein BL
Curr Hematol Malig Rep; 2021 Oct; 16(5):483-489. PubMed ID: 34499329
[TBL] [Abstract][Full Text] [Related]
42. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
[TBL] [Abstract][Full Text] [Related]
43. Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Burgstaller S; Fridrik M; Hojas S; Kühr T; Ludwig H; Mayrbäurl B; Pöhnl R; Pötscher M; Schlögl E; Zauner D; Thaler J; Gisslinger H
Wien Klin Wochenschr; 2013 Apr; 125(7-8):196-9. PubMed ID: 23536018
[TBL] [Abstract][Full Text] [Related]
44. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
45. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
46. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
[TBL] [Abstract][Full Text] [Related]
47. Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis.
Pietrasanta D; Clavio M; Vallebella E; Beltrami G; Cavaliere M; Gobbi M
Haematologica; 1997; 82(4):458-9. PubMed ID: 9299862
[TBL] [Abstract][Full Text] [Related]
48. Treatment considerations for primary myelofibrosis.
Biemond BJ
Neth J Med; 2010 Aug; 68(1):291-2. PubMed ID: 20739724
[No Abstract] [Full Text] [Related]
49. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.
Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP
Leukemia; 2003 Aug; 17(8):1669-70. PubMed ID: 12886259
[No Abstract] [Full Text] [Related]
50. Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis.
Ong A; Quach H; Leech M
J Clin Rheumatol; 2011 Jun; 17(4):211-3. PubMed ID: 21617547
[TBL] [Abstract][Full Text] [Related]
51. Current treatment of myelofibrosis.
Silver R
Clin Adv Hematol Oncol; 2005 Apr; 3(4):269-70. PubMed ID: 16166999
[No Abstract] [Full Text] [Related]
52. New and old treatment modalities in primary myelofibrosis.
Cervantes F; Mesa R; Barosi G
Cancer J; 2007; 13(6):377-83. PubMed ID: 18032975
[TBL] [Abstract][Full Text] [Related]
53. Pomalidomide.
Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
Hasselbalch HC; Clausen NT; Jensen BA
Am J Hematol; 2002 Jun; 70(2):92-9. PubMed ID: 12111781
[TBL] [Abstract][Full Text] [Related]
55. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF; Guibaud I; Bastie JN; Flesch M; Rossi JF; Lacotte-Thierry L; Boyer F; Casassus P; Slama B; Berthou C; Rodon P; Leporrier M; Villemagne B; Himberlin C; Ghomari K; Larosa F; Rollot F; Dugay J; Allard C; Maigre M; Isnard F; Zerbib R; Cauvin JM;
Haematologica; 2006 Aug; 91(8):1027-32. PubMed ID: 16885042
[TBL] [Abstract][Full Text] [Related]
56. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
[TBL] [Abstract][Full Text] [Related]
57. Myelofibrosis successfully treated with prednisolone in a patient with pachydermoperiostosis.
Ninomiya S; Hara T; Tsurumi H; Kanemura N; Kasahara S; Ogawa Y; Seishima M; Hirose Y; Moriwaki H
Intern Med; 2011; 50(19):2207-11. PubMed ID: 21963742
[TBL] [Abstract][Full Text] [Related]
58. Pomalidomide. A last-line treatment option for multiple myeloma.
Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
[TBL] [Abstract][Full Text] [Related]
59. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Schroeder G; Tefferi A
Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
[TBL] [Abstract][Full Text] [Related]
60. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]